The company, a unit of French drug maker Sanofi-Aventis, said total sales slid 4.7% to RON121 million, from RON127 million in the first half of 2010.
Zentiva posted total revenue of RON135.6 million in the January-June period, up 3.6% on the year, while overall costs fell modestly to RON98.8 million, from RON98.9 million in the same interval of 2010.
The company has a share capital of RON41.6 million split into 416.9 million shares with a face value of RON0.1.
French group Sanofi-Aventis owns 74.9% in Zentiva Romania.
At 11:00 local time, Zentiva traded up 5.66% at RON0.84 a share in Bucharest. (EUR1=RON4.2855)